Tatva Chintan Pharma Chem · NSE: TATVA · BSE: 543321
Q2 FY24 results · Jul–Sep 2023
Tatva Chintan Pharma Chem reported revenue from operations of ₹96.67 crore (up 7.3% from Q2 FY23) and net profit of ₹7.78 crore (up 9.4% from Q2 FY23) for Q2 FY24 (Jul–Sep 2023), on a consolidated basis.
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 96.67 | 90.09 | +7.3% | 114.36 | −15.5% |
| Other income | 0.76 | 1.55 | −51.2% | 1.01 | −25.5% |
| Total income | 97.42 | 91.64 | +6.3% | 115.38 | −15.6% |
| Profit before tax | 11.21 | 9.06 | +23.8% | 13.42 | −16.4% |
| Net profit for the period | 7.78 | 7.11 | +9.4% | 9.50 | −18.1% |
| EPS, basic (₹) | 3.43 | 3.21 | +6.9% | 4.29 | −20.0% |
| Net margin (%) | 8.0 | 7.9 | 8.3 |
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 92.57 | 84.04 | +10.2% | 106.11 | −12.8% |
| Other income | 0.76 | 1.55 | −51.2% | 1.01 | −25.5% |
| Total income | 93.33 | 85.59 | +9.0% | 107.12 | −12.9% |
| Profit before tax | 11.71 | 6.81 | +71.8% | 11.72 | −0.1% |
| Net profit for the period | 8.20 | 5.26 | +56.1% | 8.25 | −0.5% |
| EPS, basic (₹) | 3.63 | 2.37 | +53.2% | 3.72 | −2.4% |
| Net margin (%) | 8.9 | 6.3 | 7.8 |
Consolidated
- Filed with BSE
- 17 Nov 2023, 16:26 IST
- Board meeting
- 02 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 17 Nov 2023, 16:26 IST
- Board meeting
- 02 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE